CA
BIO icon

Continuum Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

Continuum Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7K Buy
+67
New +$19K ﹤0.01% 1052
2025
Q2 		– Sell
-15
Closed -$3.65K – 531
2025
Q1 		$3.65K Sell
15
-9
-38% -$2.71K ﹤0.01% 1178
2024
Q4 		$7.88K Buy
24
+6
+33% +$2.04K ﹤0.01% 1044
2024
Q3 		$6.3K Buy
18
+2
+13% +$635 ﹤0.01% 1102
2024
Q2 		$4.37K Hold
16
– – ﹤0.01% 1103
2024
Q1 		$4.44K Buy
+16
New +$5.26K ﹤0.01% 1084

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Continuum Advisory's BIO Position: Q2 2026 in Review

Continuum Advisory opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 67 shares worth $19.7K. The stake represents ﹤0.01% of the portfolio and ranks #1052 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in BIO as recently as Q1 2025.

Continuum Advisory first reported a position in BIO in Q1 2024 and has held it in 6 quarters since. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Continuum Advisory held 67 shares of Bio-Rad Laboratories Class A worth $19.7K as of Q2 2026.
  • Bio-Rad Laboratories Class A was a new Continuum Advisory position in Q2 2026.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1052 holding.
  • Continuum Advisory first reported a position in Bio-Rad Laboratories Class A in Q1 2024 and has held it in 6 quarters since.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.